For research and educational purposes only. Not medical advice.
Thymosin Beta-4 Reference
Educational, not medical advice reference for Thymosin Beta-4: Recovery; regulatory status, evidence posture, source review, and schedule notes.…
Reference summary
The literature is a mix of animal regeneration studies and newer translational cardiac work, including a small placebo-controlled STEMI trial. TB-500 marketing claims still extrapolate from full-length Tbeta4 rather than a settled human TB-500 evidence base.
Regulatory and posture
- Categories
- Recovery
- Aliases
- Thymosin beta-4, TB4, TB4 full peptide
- Evidence posture
- translational - Human translational data are narrow and do not establish a general recovery protocol.
- Regulatory status
- No FDA-approved injectable thymosin beta-4 drug label. Human translational work exists, but product identity differs from commercial TB-500 fragments and no routine approved protocol exists.
- Content review status
- research reference
Selected public sources
- FDA bulk drug substances with significant safety risks
- PubMed: thymosin beta 4 STEMI trial
- PubMed: thymosin beta 4 post-MI caution study
Related tools
- Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
- BAC water calculator - Solve BAC water volume for a target concentration.
- Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
- Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
- Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
- Injection-site rotation overview - Public overview of the Pro site-rotation planner.